Omeros Corporation
OMER Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Recent trades of OMER by members of U.S. Congress
OMER Stock Insider Trading Activity
Follow @QuiverQuant for major insider updates
---
Closing Price
Purchase
Sale
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
OMER Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
OMER Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in OMER holdings by institutional investors
Quarterly net insider trading by OMER's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Backtest Start Date
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Subscribe to Quiver Premium for insider trading alerts
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$90,000 Jan 20, 2026 Issue: Medical/Disease Research/Clinical Labs
-
$90,000 Oct 20, 2025 Issue: Medical/Disease Research/Clinical Labs
-
$30,000 Oct 09, 2025 Issue: Medicare/Medicaid Health Issues
-
$80,000 Jul 21, 2025 Issue: Budget/Appropriations Health Issues
-
$50,000 Jul 21, 2025 Issue: Medical/Disease Research/Clinical Labs
-
$40,000 Jul 14, 2025 Issue: Medicare/Medicaid Health Issues
-
$20,000 Jun 11, 2025 Issue: Health Issues
-
$45,000 May 06, 2025 Issue: Medicare/Medicaid
-
$60,000 Apr 21, 2025 Issue: Health Issues
-
$45,000 Apr 20, 2025 Issue: Medicare/Medicaid
-
$40,000 Apr 18, 2025 Issue: Medicare/Medicaid Health Issues
-
$50,000 Apr 15, 2025 Issue: Medical/Disease Research/Clinical Labs Health Issues
-
$45,000 Feb 04, 2025 Issue: Medicare/Medicaid
-
$60,000 Jan 21, 2025 Issue: Health Issues
-
$80,000 Jan 21, 2025 Issue: Medicare/Medicaid Budget/Appropriations
-
$45,000 Jan 21, 2025 Issue: Medicare/Medicaid
-
$75,000 Jan 13, 2025 Issue: Medical/Disease Research/Clinical Labs Health Issues
-
$80,000 Jan 13, 2025 Issue: Medicare/Medicaid Health Issues
-
$45,000 Oct 24, 2024 Issue: Medicare/Medicaid
-
$60,000 Oct 21, 2024 Issue: Health Issues
-
$80,000 Oct 21, 2024 Issue: Budget/Appropriations Medicare/Medicaid
-
$45,000 Oct 18, 2024 Issue: Medicare/Medicaid
-
$75,000 Oct 14, 2024 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$80,000 Oct 10, 2024 Issue: Medicare/Medicaid
-
$45,000 Aug 12, 2024 Issue: Medicare/Medicaid
-
$80,000 Jul 22, 2024 Issue: Budget/Appropriations Medicare/Medicaid
-
$60,000 Jul 22, 2024 Issue: Health Issues
-
$75,000 Jul 19, 2024 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$80,000 Jul 18, 2024 Issue: Medicare/Medicaid
-
$45,000 Jul 15, 2024 Issue: Medicare/Medicaid
-
$60,000 Jan 22, 2024 Issue: Health Issues
-
$45,000 Jan 22, 2024 Issue: Medicare/Medicaid
-
$80,000 Jan 22, 2024 Issue: Health Issues Medicare/Medicaid
-
$45,000 Jan 22, 2024 Issue: Medicare/Medicaid
-
$80,000 Jan 20, 2024 Issue: Medicare/Medicaid
-
$75,000 Jan 11, 2024 Issue: Medical/Disease Research/Clinical Labs
-
$60,000 Oct 20, 2023 Issue: Health Issues
-
$80,000 Oct 20, 2023 Issue: Medicare/Medicaid
-
$45,000 Oct 20, 2023 Issue: Medicare/Medicaid
-
$45,000 Oct 19, 2023 Issue: Medicare/Medicaid
-
$80,000 Oct 18, 2023 Issue: Medicare/Medicaid
-
$75,000 Oct 02, 2023 Issue: Medical/Disease Research/Clinical Labs
-
$45,000 Jul 20, 2023 Issue: Medicare/Medicaid
-
$60,000 Jul 20, 2023 Issue: Health Issues
-
$80,000 Jul 20, 2023 Issue: Medicare/Medicaid
-
$45,000 Jul 19, 2023 Issue: Medicare/Medicaid
-
$80,000 Jul 13, 2023 Issue: None
-
$45,000 Feb 23, 2023 Issue: Medicare/Medicaid
-
$60,000 Feb 19, 2023 Issue: Health Issues
-
$45,000 Jan 20, 2023 Issue: Medicare/Medicaid
-
$80,000 Jan 20, 2023 Issue: Health Issues Medicare/Medicaid
-
$80,000 Jan 20, 2023 Issue: Medicare/Medicaid
-
$80,000 Jan 13, 2023 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$45,000 Nov 02, 2022 Issue: Medicare/Medicaid
-
$60,000 Oct 20, 2022 Issue: Health Issues
-
$80,000 Oct 20, 2022 Issue: Health Issues Medicare/Medicaid
-
$45,000 Oct 19, 2022 Issue: Medicare/Medicaid
-
$80,000 Oct 18, 2022 Issue: Medicare/Medicaid
-
$80,000 Oct 08, 2022 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$60,000 Jul 20, 2022 Issue: Health Issues
-
$45,000 Jul 20, 2022 Issue: Medicare/Medicaid
-
$80,000 Jul 20, 2022 Issue: Health Issues Medicare/Medicaid
-
$45,000 Jul 20, 2022 Issue: Medicare/Medicaid
-
$80,000 Jul 18, 2022 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$80,000 Jul 18, 2022 Issue: Government Issues Medicare/Medicaid
-
$60,000 Apr 20, 2022 Issue: Health Issues
-
$80,000 Apr 20, 2022 Issue: Health Issues Medicare/Medicaid
-
$45,000 Apr 20, 2022 Issue: Medicare/Medicaid
-
$45,000 Apr 20, 2022 Issue: Medicare/Medicaid
-
$80,000 Apr 12, 2022 Issue: Government Issues Medicare/Medicaid
-
$80,000 Apr 10, 2022 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$45,000 Feb 09, 2022 Issue: Medicare/Medicaid
-
$60,000 Jan 20, 2022 Issue: Health Issues
-
$45,000 Jan 20, 2022 Issue: Medicare/Medicaid
-
$80,000 Jan 19, 2022 Issue: Medicare/Medicaid Health Issues
-
$80,000 Jan 17, 2022 Issue: Government Issues Medicare/Medicaid
-
$80,000 Jan 16, 2022 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues
-
$60,000 Oct 20, 2021 Issue: Health Issues
-
$45,000 Oct 20, 2021 Issue: Medicare/Medicaid
-
$80,000 Oct 20, 2021 Issue: Medicare/Medicaid Health Issues
-
$70,000 Oct 20, 2021 Issue: Medical/Disease Research/Clinical Labs Health Issues Medicare/Medicaid
-
$80,000 Oct 20, 2021 Issue: Government Issues Medicare/Medicaid
-
$45,000 Oct 19, 2021 Issue: Medicare/Medicaid
-
$45,000 Jul 21, 2021 Issue: Medicare/Medicaid
-
$80,000 Jul 20, 2021 Issue: Medicare/Medicaid Health Issues
-
$60,000 Jul 20, 2021 Issue: Health Issues
-
$22,500 Jul 20, 2021 Issue: Medicare/Medicaid
-
$80,000 Jul 18, 2021 Issue: Medicare/Medicaid Government Issues
-
$70,000 Jul 17, 2021 Issue: Medicare/Medicaid Health Issues Medical/Disease Research/Clinical Labs
-
$45,000 Apr 20, 2021 Issue: Medicare/Medicaid
-
$60,000 Apr 20, 2021 Issue: Health Issues
-
$80,000 Apr 20, 2021 Issue: Health Issues Medicare/Medicaid
-
$60,000 Apr 19, 2021 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid
-
$22,500 Apr 16, 2021 Issue: Medicare/Medicaid
-
$80,000 Apr 16, 2021 Issue: Medicare/Medicaid
-
$60,000 Jan 21, 2021 Issue: Health Issues
-
$22,500 Jan 21, 2021 Issue: Medicare/Medicaid
-
$80,000 Jan 21, 2021 Issue: Medicare/Medicaid Health Issues
-
$80,000 Jan 20, 2021 Issue: Medicare/Medicaid
-
$45,000 Jan 20, 2021 Issue: Medicare/Medicaid
Former government officials who have lobbied for OMER
34 former government officials from 23 congressional offices at 8 lobbying firms have lobbied for OMER, most recently Jan 20, 2026.
-
Stoney Burke House Legislative Assistant, Rep. Chet Edwards (2006-2008) Chief of Staff, Rep. Will Hurd (2015-2018) -
Sarah Burke House Scheduler Rep. Mark Amodei (2012-2013), Director of Ops Rep. Aaron Schock (2013-2015), Dir. of Member Services House Repub Conference (2015-2018), Deputy Chief of Staff Rep. Jason Smith (2018-2020), Deputy Staff Director, Energy and Commerce -
Camille Lepire House Deputy Chief of Staff, Congressman Kevin Brady -
Brett Baker Congress New U.S. Senate Committee on Finance (Senators Crapo, Grassley, and Hatch)-Deputy Health Policy Director; Health Policy Dir.; Senior Policy Advsr; Policy Advisor. U.S. House of Representatives Committee on Ways and Means (Reps. Camp and Ryan) Prof. Staff
-
Patrick Raffaniello House Chief of Staff, Congressman Bill Brewster -
Doyle Bartlett House New Chief of Staff, Rep. Bill McCollum. -
Christopher Mccannell House New ​Press Secretary, Rep. Paul Kanjorski; Press Secretary, Rep. Steny Hoyer; Chief of Staff, Rep. Michael McMahon; Chief of Staff, Rep. Joseph Crowley. -
Keenan Hale House New Legislative Assistant, Rep. Al Green.
OMER Estimated quarterly lobbying spending
OMER Revenue by Segment or Geography
By Segment
By Geography
OMER Income Statement
OMER Balance Sheet
OMER Cash Flow
U.S. Patents
New OMER patent grants
-
Patent Title: Masp-2 inhibitors and methods of use Aug. 11, 2026
-
Patent Title: Solid state forms of a pde10 inhibitor Mar. 20, 2018
-
Patent Title: Pde10 inhibitors and related compositions and methods Jan. 30, 2018
-
Patent Title: Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures Jan. 02, 2018
-
Patent Title: Stable preservative-free mydriatic and anti-inflammatory solutions for injection Jan. 02, 2018
-
Patent Title: Optically active pde10 inhibitor Dec. 26, 2017
-
Patent Title: Chimeric inhibitor molecules of complement activation Nov. 14, 2017
-
Patent Title: Pde10 inhibitors and related compositions and methods Oct. 10, 2017
-
Patent Title: Anti-fzd10 monoclonal antibodies and methods for their use Oct. 03, 2017
-
Patent Title: Composition and method for diversification of target sequences Jun. 13, 2017
-
Patent Title: Mixed micelles May. 23, 2017
-
Patent Title: Processes and intermediates for the preparation of a pde10 inhibitor May. 16, 2017
-
Patent Title: Methods for treating conditions associated with masp-2 dependent complement activation May. 09, 2017
-
Patent Title: Ophthalmologic irrigation solutions and method Mar. 07, 2017
-
Patent Title: Optically active pde10 inhibitor Nov. 15, 2016
-
Patent Title: Stable preservative-free mydriatic and anti-inflammatory solutions for injection Nov. 08, 2016
-
Patent Title: Compositions for inhibiting masp-2 dependent complement activation Oct. 25, 2016
-
Patent Title: Pde10 inhibitors and related compositions and methods Sep. 06, 2016
-
Patent Title: Ophthalmologic irrigation solutions and method Jul. 26, 2016
-
Patent Title: Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution May. 24, 2016
-
Patent Title: Mixed micelles Mar. 29, 2016
-
Patent Title: Ophthalmologic irrigation solutions and method Mar. 08, 2016
-
Patent Title: Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation Feb. 09, 2016
-
Patent Title: Treatment of addiction and impulse-control disorders using pde7 inhibitors Dec. 29, 2015
-
Patent Title: Use of pde7 inhibitors for the treatment of movement disorders Sep. 01, 2015
-
Patent Title: Anti-fzd10 monoclonal antibodies and methods for their use Aug. 11, 2015
-
Patent Title: Pde10 inhibitors and related compositions and methods Aug. 11, 2015
-
Patent Title: Stable preservative-free mydriatic and anti-inflammatory solutions for injection Jun. 30, 2015
-
Patent Title: Compositions for inhibiting masp-2 dependent complement activation Apr. 21, 2015
-
Patent Title: Method of identifying transmembrane protein-interacting compounds Apr. 14, 2015
-
Patent Title: Method of identifying a compound for the treatment or prevention of obesity Apr. 07, 2015
-
Patent Title: Methods for treating conditions associated with masp-2 dependent complement activation Sep. 23, 2014
-
Patent Title: Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures Jul. 29, 2014
-
Patent Title: Pde10 inhibitors and related compositions and methods Apr. 01, 2014
-
Patent Title: Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation Feb. 18, 2014
-
Patent Title: Use of pde7 inhibitors for the treatment of movement disorders Jan. 28, 2014
-
Patent Title: Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution Dec. 17, 2013
-
Patent Title: Ophthalmologic irrigation solutions and method Nov. 19, 2013
-
Patent Title: Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation May. 28, 2013
-
Patent Title: Compositions and methods for prophylaxis and treatment of addictions Apr. 23, 2013
-
Patent Title: Vectors and methods for the mutagenesis of mammalian genes Mar. 05, 2013
-
Patent Title: Pde10 inhibitors and related compositions and methods Feb. 19, 2013
-
Patent Title: Pde10 inhibitors and related compositions and methods Jan. 01, 2013
-
Patent Title: Method of identifying transmembrane protein-interacting compounds Oct. 30, 2012
-
Patent Title: Pde10 inhibitors and related compositions and methods Oct. 02, 2012
-
Patent Title: Ophthalmologic irrigation solutions and method May. 08, 2012
-
Patent Title: Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation Jul. 05, 2011
-
Patent Title: Methods for treating conditions associated with masp-2 dependent complement activation Apr. 05, 2011
-
Patent Title: Pde10 inhibitors and related compositions and methods Aug. 31, 2010
-
Patent Title: Rotational intrathecal analgesia Jun. 15, 2010
Government Contracts
Federal grants, loans, and purchases
Government Contracts
Estimated quarterly amount awarded to OMER from public contracts
OMER News
Recent insights relating to OMER
CNBC Recommendations
Recent picks made for OMER stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in OMER
OMER Analyst Ratings
OMER Stock Forecasts
...
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
OMER Analyst Forecasts
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
Frequently Asked Questions
- Is $OMER stock a Buy, Sell, or Hold?
- What is the price target for $OMER stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
OMER Top Shareholders
|
Shareholder
|
Shares Held
|
|---|
Frequently Asked Questions
- Who owns $OMER stock?
- Who owns the most shares of $OMER stock?
- What funds own $OMER stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
OMER Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view OMER Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
About OMER
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
- Address Seattle, WA
- Market Cap 1.5 billion
- Employees 175
- Industrial Classification Pharmaceutical Preparations
Omeros Corporation (OMER) Historical Stock Prices
Omeros Corporation (OMER) closed at $20.74 on September 23, 2026. Over the past year its adjusted close ranged from $4.10 to $21.05. Daily prices go back to January 2, 2014, 3,200 trading days in all.
- 1 month+7.35%
- 3 months+96.03%
- Year to date+20.76%
- 1 year+384.58%
- 3 years+605.44%
- 5 years+30.60%
- Max+71.97%
See every congressional and insider trade on the OMER price chart
Quiver Premium charts OMER's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | 20.65 | 20.97 | 20.43 | 20.74 | 20.74 | 1,349,574 |
| Sep 22, 2026 | 19.58 | 21.24 | 19.30 | 21.05 | 21.05 | 3,958,754 |
| Sep 21, 2026 | 18.23 | 18.51 | 17.82 | 18.49 | 18.49 | 1,055,632 |
| Sep 18, 2026 | 18.69 | 18.69 | 17.68 | 17.87 | 17.87 | 2,151,925 |
| Sep 17, 2026 | 17.52 | 18.57 | 17.42 | 18.45 | 18.45 | 2,567,943 |
| Sep 16, 2026 | 17.16 | 17.99 | 17.14 | 17.34 | 17.34 | 2,108,105 |
| Sep 15, 2026 | 17.26 | 17.40 | 16.50 | 17.17 | 17.17 | 1,655,628 |
| Sep 14, 2026 | 18.30 | 18.30 | 17.42 | 17.46 | 17.46 | 1,691,497 |
| Sep 11, 2026 | 18.74 | 18.98 | 18.28 | 18.28 | 18.28 | 1,014,308 |
| Sep 10, 2026 | 19.12 | 19.24 | 18.30 | 18.59 | 18.59 | 1,231,840 |
| Sep 9, 2026 | 19.01 | 19.55 | 18.93 | 19.39 | 19.39 | 1,531,324 |
| Sep 8, 2026 | 18.70 | 19.37 | 18.52 | 19.12 | 19.12 | 1,015,537 |
| Sep 4, 2026 | 19.00 | 19.23 | 18.90 | 18.95 | 18.95 | 892,192 |
| Sep 3, 2026 | 18.99 | 19.18 | 18.70 | 19.11 | 19.11 | 1,165,465 |
| Sep 2, 2026 | 18.97 | 19.47 | 18.44 | 18.86 | 18.86 | 1,350,615 |
| Sep 1, 2026 | 18.66 | 19.04 | 18.48 | 18.75 | 18.75 | 2,042,703 |
| Aug 31, 2026 | 18.54 | 18.94 | 18.01 | 18.79 | 18.79 | 1,330,487 |
| Aug 28, 2026 | 19.02 | 19.16 | 18.42 | 18.61 | 18.61 | 1,144,032 |
| Aug 27, 2026 | 18.24 | 19.62 | 18.00 | 19.25 | 19.25 | 1,756,608 |
| Aug 26, 2026 | 18.96 | 19.08 | 18.20 | 18.22 | 18.22 | 1,409,101 |
| Aug 25, 2026 | 19.34 | 19.65 | 19.12 | 19.28 | 19.28 | 1,315,538 |
| Aug 24, 2026 | 19.10 | 19.39 | 18.42 | 19.32 | 19.32 | 1,425,780 |
| Aug 21, 2026 | 18.64 | 19.58 | 18.41 | 19.27 | 19.27 | 2,582,621 |
| Aug 20, 2026 | 18.30 | 18.73 | 18.07 | 18.63 | 18.63 | 1,649,198 |
| Aug 19, 2026 | 17.13 | 18.89 | 17.13 | 18.39 | 18.39 | 3,197,709 |
| Aug 18, 2026 | 17.02 | 17.29 | 16.90 | 17.19 | 17.19 | 1,234,652 |
| Aug 17, 2026 | 17.17 | 17.52 | 16.90 | 17.36 | 17.36 | 2,467,443 |
| Aug 14, 2026 | 17.35 | 17.61 | 16.54 | 17.19 | 17.19 | 3,675,975 |
| Aug 13, 2026 | 16.65 | 18.14 | 16.27 | 17.35 | 17.35 | 13,436,012 |
| Aug 12, 2026 | 13.50 | 13.80 | 13.29 | 13.71 | 13.71 | 3,583,213 |
| Aug 11, 2026 | 13.46 | 13.85 | 13.33 | 13.60 | 13.60 | 1,888,088 |
| Aug 10, 2026 | 13.36 | 13.64 | 13.00 | 13.62 | 13.62 | 1,390,698 |
| Aug 7, 2026 | 13.29 | 13.44 | 12.92 | 13.25 | 13.25 | 1,227,715 |
| Aug 6, 2026 | 12.44 | 13.19 | 12.27 | 13.15 | 13.15 | 841,319 |
| Aug 5, 2026 | 12.96 | 13.13 | 12.55 | 12.65 | 12.65 | 1,116,888 |
| Aug 4, 2026 | 12.66 | 13.05 | 12.42 | 12.94 | 12.94 | 1,646,306 |
| Aug 3, 2026 | 12.25 | 12.59 | 11.90 | 12.56 | 12.56 | 1,446,064 |
| Jul 31, 2026 | 11.93 | 11.99 | 11.37 | 11.84 | 11.84 | 1,309,589 |
| Jul 30, 2026 | 11.65 | 12.16 | 11.63 | 11.93 | 11.93 | 1,331,086 |
| Jul 29, 2026 | 11.36 | 11.89 | 11.24 | 11.67 | 11.67 | 1,686,053 |
| Jul 28, 2026 | 11.16 | 11.29 | 10.58 | 11.28 | 11.28 | 2,222,452 |
| Jul 27, 2026 | 11.25 | 11.65 | 10.50 | 11.34 | 11.34 | 3,360,609 |
| Jul 24, 2026 | 10.28 | 10.29 | 9.77 | 9.79 | 9.79 | 799,038 |
| Jul 23, 2026 | 9.60 | 10.36 | 9.60 | 10.28 | 10.28 | 1,544,963 |
| Jul 22, 2026 | 9.43 | 9.91 | 9.43 | 9.84 | 9.84 | 1,229,960 |
| Jul 21, 2026 | 9.72 | 9.86 | 9.34 | 9.53 | 9.53 | 1,019,774 |
| Jul 20, 2026 | 9.59 | 9.82 | 9.37 | 9.63 | 9.63 | 1,046,596 |
| Jul 17, 2026 | 9.16 | 9.91 | 9.12 | 9.69 | 9.69 | 1,195,533 |
| Jul 16, 2026 | 10.25 | 10.33 | 9.16 | 9.22 | 9.22 | 2,197,672 |
| Jul 15, 2026 | 10.55 | 10.66 | 10.33 | 10.37 | 10.37 | 1,134,963 |
| Jul 14, 2026 | 10.01 | 10.70 | 9.97 | 10.50 | 10.50 | 1,389,751 |
| Jul 13, 2026 | 10.06 | 10.22 | 9.94 | 10.01 | 10.01 | 1,220,511 |
| Jul 10, 2026 | 10.18 | 10.35 | 9.94 | 10.28 | 10.28 | 1,090,362 |
| Jul 9, 2026 | 10.28 | 10.60 | 10.17 | 10.27 | 10.27 | 875,884 |
| Jul 8, 2026 | 10.28 | 10.69 | 10.24 | 10.24 | 10.24 | 1,496,609 |
| Jul 7, 2026 | 10.33 | 10.56 | 10.12 | 10.33 | 10.33 | 1,236,226 |
| Jul 6, 2026 | 9.25 | 10.50 | 9.25 | 10.34 | 10.34 | 1,745,449 |
| Jul 2, 2026 | 9.41 | 9.62 | 9.00 | 9.28 | 9.28 | 1,375,685 |
| Jul 1, 2026 | 9.52 | 9.73 | 9.40 | 9.41 | 9.41 | 1,429,453 |
| Jun 30, 2026 | 9.99 | 10.16 | 9.50 | 9.51 | 9.51 | 1,945,049 |
| Jun 29, 2026 | 8.53 | 9.94 | 8.52 | 9.91 | 9.91 | 2,744,125 |
| Jun 26, 2026 | 7.59 | 8.89 | 7.39 | 8.67 | 8.67 | 10,918,913 |
| Jun 25, 2026 | 10.61 | 10.83 | 10.52 | 10.72 | 10.72 | 1,143,187 |
| Jun 24, 2026 | 10.57 | 10.83 | 10.46 | 10.58 | 10.58 | 1,174,601 |
| Jun 23, 2026 | 10.28 | 10.60 | 10.10 | 10.48 | 10.48 | 1,073,153 |
| Jun 22, 2026 | 10.10 | 10.47 | 9.79 | 10.33 | 10.33 | 1,699,722 |
| Jun 18, 2026 | 10.09 | 10.42 | 9.75 | 10.28 | 10.28 | 2,634,659 |
| Jun 17, 2026 | 9.44 | 9.93 | 9.26 | 9.64 | 9.64 | 1,417,148 |
| Jun 16, 2026 | 9.34 | 9.88 | 8.86 | 9.48 | 9.48 | 2,608,247 |
| Jun 15, 2026 | 8.82 | 9.61 | 8.82 | 9.33 | 9.33 | 1,960,054 |
| Jun 12, 2026 | 10.05 | 10.11 | 6.70 | 8.73 | 8.73 | 7,784,719 |
| Jun 11, 2026 | 10.19 | 10.48 | 10.02 | 10.18 | 10.18 | 1,097,428 |
| Jun 10, 2026 | 9.87 | 10.45 | 9.87 | 10.20 | 10.20 | 1,375,356 |
| Jun 9, 2026 | 9.86 | 10.04 | 9.55 | 9.97 | 9.97 | 1,544,618 |
| Jun 8, 2026 | 10.02 | 10.10 | 9.63 | 9.85 | 9.85 | 1,407,483 |
| Jun 5, 2026 | 10.23 | 10.26 | 9.75 | 9.79 | 9.79 | 1,717,308 |
| Jun 4, 2026 | 10.25 | 10.80 | 10.10 | 10.25 | 10.25 | 1,407,042 |
| Jun 3, 2026 | 10.21 | 10.22 | 9.86 | 10.16 | 10.16 | 1,850,387 |
| Jun 2, 2026 | 10.54 | 10.65 | 10.21 | 10.26 | 10.26 | 2,441,041 |
| Jun 1, 2026 | 10.91 | 11.00 | 10.61 | 10.72 | 10.72 | 1,262,125 |
| May 29, 2026 | 11.12 | 11.12 | 10.77 | 11.04 | 11.04 | 2,596,693 |
| May 28, 2026 | 10.84 | 11.21 | 10.58 | 11.15 | 11.15 | 1,194,448 |
| May 27, 2026 | 11.77 | 12.02 | 10.55 | 11.07 | 11.07 | 4,359,134 |
| May 26, 2026 | 11.55 | 12.00 | 11.46 | 11.65 | 11.65 | 1,170,484 |
| May 22, 2026 | 11.84 | 11.97 | 11.46 | 11.46 | 11.46 | 1,525,924 |
| May 21, 2026 | 12.38 | 12.55 | 11.92 | 11.96 | 11.96 | 1,096,337 |
| May 20, 2026 | 12.23 | 12.55 | 12.00 | 12.38 | 12.38 | 1,052,838 |
| May 19, 2026 | 11.57 | 11.98 | 11.41 | 11.97 | 11.97 | 1,374,098 |
| May 18, 2026 | 12.29 | 12.35 | 11.66 | 11.70 | 11.70 | 1,988,371 |
| May 15, 2026 | 12.86 | 13.00 | 11.80 | 12.25 | 12.25 | 3,266,355 |
| May 14, 2026 | 14.54 | 14.72 | 12.51 | 13.28 | 13.28 | 3,446,003 |
| May 13, 2026 | 14.77 | 14.86 | 13.78 | 14.38 | 14.38 | 2,377,106 |
| May 12, 2026 | 14.48 | 14.94 | 14.33 | 14.76 | 14.76 | 1,100,077 |
| May 11, 2026 | 14.14 | 14.76 | 14.13 | 14.36 | 14.36 | 800,492 |
| May 8, 2026 | 14.62 | 14.83 | 14.12 | 14.13 | 14.13 | 863,194 |
| May 7, 2026 | 14.86 | 14.88 | 14.36 | 14.64 | 14.64 | 737,861 |
| May 6, 2026 | 14.77 | 14.91 | 14.63 | 14.83 | 14.83 | 539,604 |
| May 5, 2026 | 14.98 | 15.05 | 14.63 | 14.77 | 14.77 | 779,081 |
| May 4, 2026 | 15.03 | 15.25 | 14.69 | 14.91 | 14.91 | 1,087,977 |
| May 1, 2026 | 14.57 | 15.32 | 14.45 | 15.06 | 15.06 | 1,282,110 |
| Apr 30, 2026 | 14.72 | 14.92 | 14.57 | 14.60 | 14.60 | 712,574 |
| Apr 29, 2026 | 14.64 | 14.72 | 14.37 | 14.56 | 14.56 | 856,129 |
| Apr 28, 2026 | 14.65 | 14.89 | 14.30 | 14.67 | 14.67 | 1,618,912 |
| Apr 27, 2026 | 13.50 | 14.99 | 13.48 | 14.74 | 14.74 | 1,913,939 |
| Apr 24, 2026 | 13.52 | 13.92 | 13.04 | 13.53 | 13.53 | 1,523,877 |
| Apr 23, 2026 | 13.32 | 13.70 | 13.01 | 13.52 | 13.52 | 869,162 |
| Apr 22, 2026 | 13.52 | 13.59 | 13.21 | 13.37 | 13.37 | 890,466 |
| Apr 21, 2026 | 13.40 | 13.50 | 13.02 | 13.26 | 13.26 | 829,013 |
| Apr 20, 2026 | 13.35 | 13.94 | 13.04 | 13.47 | 13.47 | 1,127,979 |
| Apr 17, 2026 | 12.59 | 13.46 | 12.45 | 13.44 | 13.44 | 1,953,030 |
| Apr 16, 2026 | 12.48 | 12.60 | 12.09 | 12.54 | 12.54 | 1,092,175 |
| Apr 15, 2026 | 11.98 | 12.57 | 11.92 | 12.25 | 12.25 | 1,159,429 |
| Apr 14, 2026 | 11.48 | 11.84 | 11.46 | 11.84 | 11.84 | 776,502 |
| Apr 13, 2026 | 11.41 | 11.65 | 11.25 | 11.38 | 11.38 | 797,850 |
| Apr 10, 2026 | 12.02 | 12.02 | 11.46 | 11.49 | 11.49 | 970,358 |
| Apr 9, 2026 | 11.40 | 11.94 | 11.36 | 11.91 | 11.91 | 1,280,813 |
| Apr 8, 2026 | 11.33 | 11.60 | 10.93 | 11.51 | 11.51 | 1,191,210 |
| Apr 7, 2026 | 10.80 | 11.00 | 10.41 | 10.98 | 10.98 | 1,237,784 |
| Apr 6, 2026 | 10.94 | 11.27 | 10.70 | 10.88 | 10.88 | 1,029,375 |
| Apr 2, 2026 | 11.62 | 11.81 | 10.82 | 10.90 | 10.90 | 1,837,300 |
| Apr 1, 2026 | 11.32 | 13.00 | 11.29 | 12.08 | 12.08 | 4,639,001 |
| Mar 31, 2026 | 10.00 | 10.62 | 9.99 | 10.56 | 10.56 | 1,793,020 |
| Mar 30, 2026 | 9.95 | 10.05 | 9.77 | 9.81 | 9.81 | 1,081,760 |
| Mar 27, 2026 | 10.40 | 10.41 | 9.86 | 9.88 | 9.88 | 877,096 |
| Mar 26, 2026 | 10.33 | 10.70 | 10.21 | 10.30 | 10.30 | 559,951 |
| Mar 25, 2026 | 10.36 | 10.73 | 10.29 | 10.44 | 10.44 | 633,371 |
| Mar 24, 2026 | 10.50 | 10.59 | 10.04 | 10.18 | 10.18 | 956,723 |
| Mar 23, 2026 | 11.17 | 11.44 | 10.59 | 10.66 | 10.66 | 1,185,912 |
| Mar 20, 2026 | 11.07 | 11.22 | 10.89 | 11.00 | 11.00 | 1,318,574 |
| Mar 19, 2026 | 10.83 | 11.27 | 10.66 | 11.12 | 11.12 | 650,430 |
| Mar 18, 2026 | 11.18 | 11.18 | 10.75 | 10.95 | 10.95 | 783,939 |
| Mar 17, 2026 | 11.17 | 11.38 | 11.01 | 11.27 | 11.27 | 631,030 |
| Mar 16, 2026 | 11.29 | 11.40 | 11.09 | 11.14 | 11.14 | 491,404 |
| Mar 13, 2026 | 11.56 | 11.71 | 11.12 | 11.19 | 11.19 | 750,063 |
| Mar 12, 2026 | 11.66 | 11.74 | 11.28 | 11.42 | 11.42 | 722,278 |
| Mar 11, 2026 | 11.62 | 11.98 | 11.51 | 11.93 | 11.93 | 554,932 |
| Mar 10, 2026 | 11.26 | 11.93 | 11.22 | 11.71 | 11.71 | 815,697 |
| Mar 9, 2026 | 11.36 | 11.64 | 11.15 | 11.29 | 11.29 | 1,019,253 |
| Mar 6, 2026 | 11.33 | 11.66 | 11.15 | 11.54 | 11.54 | 622,817 |
| Mar 5, 2026 | 11.50 | 11.69 | 11.33 | 11.49 | 11.49 | 887,264 |
| Mar 4, 2026 | 11.68 | 11.88 | 11.37 | 11.59 | 11.59 | 879,372 |
| Mar 3, 2026 | 11.54 | 11.76 | 11.22 | 11.64 | 11.64 | 710,146 |
| Mar 2, 2026 | 11.79 | 12.13 | 11.67 | 11.98 | 11.98 | 896,137 |
| Feb 27, 2026 | 11.37 | 12.07 | 11.37 | 12.05 | 12.05 | 1,205,919 |
| Feb 26, 2026 | 11.38 | 11.58 | 11.28 | 11.55 | 11.55 | 537,888 |
| Feb 25, 2026 | 11.60 | 11.78 | 11.31 | 11.38 | 11.38 | 687,669 |
| Feb 24, 2026 | 11.37 | 11.83 | 11.36 | 11.55 | 11.55 | 866,371 |
| Feb 23, 2026 | 11.96 | 12.13 | 11.09 | 11.44 | 11.44 | 1,439,755 |
| Feb 20, 2026 | 11.86 | 12.22 | 11.73 | 12.04 | 12.04 | 1,007,423 |
| Feb 19, 2026 | 11.62 | 12.15 | 11.62 | 12.01 | 12.01 | 728,844 |
| Feb 18, 2026 | 11.87 | 12.24 | 11.66 | 11.75 | 11.75 | 840,450 |
| Feb 17, 2026 | 11.93 | 12.45 | 11.75 | 11.93 | 11.93 | 955,447 |
| Feb 13, 2026 | 11.54 | 12.14 | 11.45 | 11.69 | 11.69 | 792,865 |
| Feb 12, 2026 | 11.21 | 11.54 | 11.05 | 11.44 | 11.44 | 653,911 |
| Feb 11, 2026 | 11.24 | 11.45 | 11.00 | 11.23 | 11.23 | 844,775 |
| Feb 10, 2026 | 11.34 | 11.46 | 11.12 | 11.17 | 11.17 | 525,493 |
| Feb 9, 2026 | 11.18 | 11.45 | 11.01 | 11.30 | 11.30 | 629,707 |
| Feb 6, 2026 | 11.00 | 11.41 | 10.89 | 11.23 | 11.23 | 1,250,870 |
| Feb 5, 2026 | 11.30 | 11.76 | 10.55 | 10.74 | 10.74 | 1,819,375 |
| Feb 4, 2026 | 11.84 | 11.96 | 11.30 | 11.51 | 11.51 | 1,395,113 |
| Feb 3, 2026 | 11.74 | 12.18 | 11.61 | 11.82 | 11.82 | 1,126,186 |
| Feb 2, 2026 | 11.60 | 11.88 | 11.44 | 11.72 | 11.72 | 1,173,651 |
| Jan 30, 2026 | 11.84 | 12.17 | 11.61 | 11.69 | 11.69 | 1,379,375 |
| Jan 29, 2026 | 11.78 | 12.08 | 11.66 | 11.95 | 11.95 | 838,215 |
| Jan 28, 2026 | 12.61 | 12.64 | 11.76 | 11.81 | 11.81 | 1,373,206 |
| Jan 27, 2026 | 11.53 | 12.68 | 11.45 | 12.67 | 12.67 | 1,603,632 |
| Jan 26, 2026 | 11.81 | 11.82 | 11.52 | 11.53 | 11.53 | 1,478,315 |
| Jan 23, 2026 | 12.16 | 12.21 | 11.88 | 11.93 | 11.93 | 1,175,442 |
| Jan 22, 2026 | 12.01 | 12.50 | 11.99 | 12.15 | 12.15 | 2,065,740 |
| Jan 21, 2026 | 12.05 | 12.60 | 11.69 | 12.08 | 12.08 | 2,230,993 |
| Jan 20, 2026 | 11.94 | 12.47 | 11.52 | 12.26 | 12.26 | 2,268,625 |
| Jan 16, 2026 | 12.18 | 12.21 | 11.71 | 12.01 | 12.01 | 2,680,380 |
| Jan 15, 2026 | 12.85 | 12.93 | 11.92 | 12.21 | 12.21 | 2,468,310 |
| Jan 14, 2026 | 12.58 | 13.26 | 12.53 | 13.08 | 13.08 | 1,876,523 |
| Jan 13, 2026 | 12.52 | 12.64 | 12.11 | 12.62 | 12.62 | 2,176,383 |
| Jan 12, 2026 | 12.22 | 13.09 | 11.85 | 12.82 | 12.82 | 4,019,723 |
| Jan 9, 2026 | 13.66 | 14.25 | 12.45 | 12.49 | 12.49 | 4,588,809 |
| Jan 8, 2026 | 14.52 | 16.14 | 13.41 | 13.45 | 13.45 | 4,967,025 |
| Jan 7, 2026 | 13.61 | 14.61 | 13.60 | 14.09 | 14.09 | 4,290,098 |
| Jan 6, 2026 | 15.09 | 15.12 | 13.51 | 13.53 | 13.53 | 5,317,422 |
| Jan 5, 2026 | 16.37 | 16.39 | 15.29 | 15.40 | 15.40 | 2,997,729 |
| Jan 2, 2026 | 17.50 | 17.63 | 16.29 | 16.38 | 16.38 | 2,843,564 |
| Dec 31, 2025 | 16.68 | 17.34 | 16.13 | 17.18 | 17.18 | 2,807,076 |
| Dec 30, 2025 | 16.57 | 17.47 | 16.00 | 16.96 | 16.96 | 4,257,290 |
| Dec 29, 2025 | 15.17 | 16.64 | 14.43 | 16.57 | 16.57 | 5,563,350 |
| Dec 26, 2025 | 15.35 | 15.87 | 14.21 | 15.71 | 15.71 | 7,163,986 |
| Dec 24, 2025 | 16.44 | 17.65 | 13.92 | 15.36 | 15.36 | 24,509,175 |
| Dec 23, 2025 | 9.43 | 9.65 | 8.60 | 8.75 | 8.75 | 2,520,345 |
| Dec 22, 2025 | 9.62 | 10.26 | 9.50 | 9.51 | 9.51 | 2,613,230 |
| Dec 19, 2025 | 9.25 | 9.93 | 9.25 | 9.60 | 9.60 | 2,346,173 |
| Dec 18, 2025 | 8.92 | 9.35 | 8.91 | 9.16 | 9.16 | 996,962 |
| Dec 17, 2025 | 8.80 | 9.30 | 8.72 | 8.83 | 8.83 | 1,359,122 |
| Dec 16, 2025 | 9.02 | 9.18 | 8.27 | 8.77 | 8.77 | 2,533,801 |
| Dec 15, 2025 | 10.20 | 10.24 | 9.19 | 9.20 | 9.20 | 1,958,552 |
| Dec 12, 2025 | 10.61 | 10.71 | 10.15 | 10.15 | 10.15 | 1,118,341 |
| Dec 11, 2025 | 11.09 | 11.42 | 10.35 | 10.59 | 10.59 | 1,566,976 |
| Dec 10, 2025 | 11.47 | 11.71 | 11.22 | 11.24 | 11.24 | 1,200,868 |
| Dec 9, 2025 | 11.28 | 11.65 | 11.13 | 11.47 | 11.47 | 1,101,173 |
| Dec 8, 2025 | 11.01 | 11.44 | 10.82 | 11.40 | 11.40 | 1,309,426 |
| Dec 5, 2025 | 10.94 | 11.00 | 10.61 | 10.85 | 10.85 | 1,034,969 |
| Dec 4, 2025 | 10.52 | 11.03 | 10.34 | 11.03 | 11.03 | 1,267,557 |
| Dec 3, 2025 | 9.43 | 10.68 | 9.31 | 10.62 | 10.62 | 1,772,180 |
| Dec 2, 2025 | 9.67 | 10.08 | 9.42 | 9.43 | 9.43 | 1,406,010 |
| Dec 1, 2025 | 9.83 | 10.41 | 9.56 | 9.68 | 9.68 | 2,578,097 |
| Nov 28, 2025 | 9.68 | 9.93 | 9.57 | 9.69 | 9.69 | 594,031 |
| Nov 26, 2025 | 9.70 | 9.84 | 9.50 | 9.63 | 9.63 | 1,027,986 |
| Nov 25, 2025 | 9.68 | 9.80 | 9.34 | 9.45 | 9.45 | 1,307,583 |
| Nov 24, 2025 | 8.92 | 10.00 | 8.90 | 9.76 | 9.76 | 2,516,073 |
| Nov 21, 2025 | 8.05 | 8.91 | 8.04 | 8.87 | 8.87 | 1,225,957 |
| Nov 20, 2025 | 8.39 | 8.60 | 8.20 | 8.23 | 8.23 | 1,271,442 |
| Nov 19, 2025 | 8.41 | 8.74 | 8.20 | 8.22 | 8.22 | 1,362,396 |
| Nov 18, 2025 | 9.00 | 9.55 | 8.48 | 8.50 | 8.50 | 2,396,828 |
| Nov 17, 2025 | 7.90 | 9.10 | 7.72 | 9.08 | 9.08 | 3,849,499 |
| Nov 14, 2025 | 6.64 | 7.89 | 6.59 | 7.87 | 7.87 | 4,819,835 |
| Nov 13, 2025 | 6.84 | 6.88 | 6.24 | 6.28 | 6.28 | 2,084,150 |
| Nov 12, 2025 | 6.89 | 7.04 | 6.81 | 6.89 | 6.89 | 1,087,817 |
| Nov 11, 2025 | 6.61 | 7.06 | 6.52 | 6.89 | 6.89 | 1,223,402 |
| Nov 10, 2025 | 6.68 | 6.81 | 6.53 | 6.60 | 6.60 | 1,124,449 |
| Nov 7, 2025 | 6.50 | 6.62 | 6.25 | 6.59 | 6.59 | 1,254,619 |
| Nov 6, 2025 | 6.99 | 7.03 | 6.56 | 6.58 | 6.58 | 1,576,533 |
| Nov 5, 2025 | 6.69 | 7.02 | 6.64 | 6.99 | 6.99 | 1,298,568 |
| Nov 4, 2025 | 7.06 | 7.24 | 6.71 | 6.73 | 6.73 | 1,474,343 |
| Nov 3, 2025 | 7.21 | 7.35 | 7.07 | 7.17 | 7.17 | 1,371,128 |
| Oct 31, 2025 | 7.54 | 7.54 | 7.22 | 7.33 | 7.33 | 1,537,659 |
| Oct 30, 2025 | 7.58 | 7.94 | 7.50 | 7.52 | 7.52 | 1,081,214 |
| Oct 29, 2025 | 8.00 | 8.02 | 7.51 | 7.68 | 7.68 | 1,416,792 |
| Oct 28, 2025 | 7.73 | 8.05 | 7.44 | 7.96 | 7.96 | 1,800,957 |
| Oct 27, 2025 | 7.66 | 7.82 | 7.51 | 7.71 | 7.71 | 943,196 |
| Oct 24, 2025 | 7.71 | 7.85 | 7.53 | 7.55 | 7.55 | 1,341,108 |
| Oct 23, 2025 | 7.93 | 7.95 | 7.60 | 7.65 | 7.65 | 1,350,841 |
| Oct 22, 2025 | 7.77 | 8.03 | 7.42 | 7.74 | 7.74 | 1,923,860 |
| Oct 21, 2025 | 8.10 | 8.32 | 7.77 | 7.87 | 7.87 | 2,363,737 |
| Oct 20, 2025 | 7.97 | 8.37 | 7.86 | 8.25 | 8.25 | 2,577,673 |
| Oct 17, 2025 | 9.61 | 9.66 | 7.96 | 8.11 | 8.11 | 7,479,440 |
| Oct 16, 2025 | 9.15 | 10.36 | 8.95 | 9.83 | 9.83 | 11,176,197 |
| Oct 15, 2025 | 11.59 | 12.10 | 9.19 | 10.42 | 10.42 | 125,220,957 |
| Oct 14, 2025 | 4.15 | 4.19 | 4.05 | 4.10 | 4.10 | 731,976 |
| Oct 13, 2025 | 4.30 | 4.30 | 4.09 | 4.19 | 4.19 | 1,030,658 |
| Oct 10, 2025 | 4.59 | 4.59 | 4.15 | 4.19 | 4.19 | 1,263,754 |
| Oct 9, 2025 | 4.43 | 4.59 | 4.38 | 4.56 | 4.56 | 1,041,001 |
| Oct 8, 2025 | 4.45 | 4.53 | 4.36 | 4.39 | 4.39 | 528,807 |
| Oct 7, 2025 | 4.61 | 4.69 | 4.41 | 4.44 | 4.44 | 669,084 |
| Oct 6, 2025 | 4.62 | 4.72 | 4.46 | 4.61 | 4.61 | 1,477,551 |
| Oct 3, 2025 | 4.29 | 4.59 | 4.26 | 4.58 | 4.58 | 1,231,641 |
| Oct 2, 2025 | 4.14 | 4.24 | 4.08 | 4.22 | 4.22 | 785,548 |
| Oct 1, 2025 | 4.10 | 4.18 | 4.07 | 4.14 | 4.14 | 858,085 |
| Sep 30, 2025 | 4.16 | 4.18 | 4.08 | 4.10 | 4.10 | 714,322 |
| Sep 29, 2025 | 4.52 | 4.52 | 4.14 | 4.18 | 4.18 | 841,937 |
| Sep 26, 2025 | 4.39 | 4.52 | 4.25 | 4.46 | 4.46 | 1,011,933 |
| Sep 25, 2025 | 4.20 | 4.41 | 4.13 | 4.38 | 4.38 | 1,186,351 |
| Sep 24, 2025 | 4.33 | 4.36 | 4.17 | 4.20 | 4.20 | 982,810 |
| Sep 23, 2025 | 4.30 | 4.54 | 4.27 | 4.28 | 4.28 | 1,413,050 |
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
Need daily prices for every ticker, in code?
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver API
Omeros Corporation Executive Compensation
We estimate that -- received a compensation of -- in --, making them the highest paid executive at OMER, per a recent SEC DEF 14A filing. We estimate that the median employee at OMEROS CORP is paid $183,614.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|